|
- 品牌：MedKoo
- 產(chǎn)地：美國
- 貨號(hào)：300330
- cas：106308-44-5
- 發(fā)布日期： 2022-07-20
- 更新日期： 2024-08-12
| 產(chǎn)地 | 美國 |
| 品牌 | MedKoo |
| 貨號(hào) | 300330 |
| 用途 | This product is for research use only, not for human or veterinary use. |
| 包裝規(guī)格 | 100.0mg; 200.0mg; 500.0mg; 1.0g; 2.0g; 5.0g; 10.0g; 20.0g; |
| CAS編號(hào) | 106308-44-5 |
| 純度 | >98%% |
| 是否進(jìn)口 | 是 |
Description: Rufinamide is a board spectrum anticonvulsant. It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome and various other seizure disorders. Rufinamide was approved by the US Food and Drug Administration on November 14, 2008 as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults. Rufinamide has efficacy for partial seizures. Rufinamide prolongs the inactivation of sodium channels and limits the frequency of action potential firing in cultured and acutely isolated neurons.
Synonym: CGP-33101; CGP 33101; CGP33101; Brand name: BANZEL; Inovelon.
IUPAC/Chemical Name: 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
InChi Key: POGQSBRIGCQNEG-UHFFFAOYSA-N
InChi Code: InChI=1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)
SMILES Code: O=C(C1=CN(CC2=C(F)C=CC=C2F)N=N1)N
Appearance: XXXX solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO.
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
